EP. 1: Biology of RET Genetic Alterations
EP. 2: Multikinase TKIs for RET Fusion+ NSCLC
EP. 3: Optimal Detection of RET Fusions
EP. 4: Use of Liquid Biopsy for RET Detection
EP. 5: Best Practices for NGS Selection in NSCLC
EP. 6: FDA Approval of RET Inhibitors in NSCLC
EP. 7: Importance of Frontline RET Inhibition in NSCLC
EP. 8: Intracranial Response Rates from RET Inhibitors
EP. 9: RET Fusion+ NSCLC and COVID-19
EP. 10: Next Steps for RET Fusion+ NSCLC
EP. 11: Epidemiology of Medullary Thyroid Cancer
EP. 12: Actionable Driver Mutations in Medullary Thyroid Cancer
EP. 13: Multikinase TKIs in Medullary Thyroid Cancer
EP. 14: Recent Approval of Selpercatinib in RET-Mutated MTC
EP. 15: Next Steps for RET-Mutated Medullary Thyroid Cancer
Oncology Experts Preview Top Abstracts From 2025 ASCO GU
Dr Somaiah on Ongoing Research With Novel Agents in Sarcomas
Dr Hamid on the Potential for Cancer Vaccines in Melanoma
Dr Orloff on Treatment Strategies for Rapidly Progressing Uveal Melanoma